Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Last trade$122.12
Day change-$3.735 (-2.97%)
Day range$119.57 – $126.07
Volume442,673
Market cap$10.74B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.74B
Price / earnings
—
Price / book
6.65×
Price / sales
105.09×
EV / sales
101.46×
EV / EBITDA
-26.14×
Profitability
Earnings per share
-$4.09
Return on assets
-19.77%
Return on equity
-21.64%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.13×
Quick ratio
11.13×
Cash ratio
4.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$288.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KYMR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$65M
$34.37M
$2.87M
$2.76M
$11.48M
$22.1M
$7.39M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$65M
$34.37M
$2.87M
$2.76M
$11.48M
$22.1M
$7.39M
Selling, general and administrative
$18.72M
$21.13M
$20.36M
$16.94M
$17.34M
$17.65M
$16.27M
$16.33M
Research and development
$128.51M
$119.48M
$98.16M
$83.83M
$74.09M
$78.39M
$80.26M
$71.82M
Total operating expenses
$147.23M
$140.61M
$118.58M
$100.77M
$95.29M
$96.03M
$96.6M
$88.15M
Operating income
-$147.23M
-$75.61M
-$84.22M
-$97.9M
-$92.52M
-$84.56M
-$74.5M
-$80.76M
Interest expense
-$62K
$14.48M
$0
$280K
-$98K
$8.05M
$0
$190K
Income before taxes
-$132M
-$61.21M
-$69.23M
-$86.98M
-$82.18M
-$76.61M
-$65.58M
-$70.75M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$132M
-$61.21M
-$69.23M
-$86.98M
-$82.18M
-$76.61M
-$65.58M
-$70.75M
Net income attributable to common shareholders
-$132M
-$61.21M
-$69.23M
-$86.98M
-$82.18M
-$76.61M
-$65.58M
-$70.75M
EBITDA
-$145.21M
-$73.58M
-$82.19M
-$95.86M
-$86.52M
-$82.47M
-$72.45M
-$78.77M
Basic earnings per share
-$1.32
-$0.62
-$0.71
-$0.97
-$0.94
-$0.95
-$0.82
-$0.88
Diluted earnings per share
-$1.32
-$0.62
-$0.71
-$0.97
-$0.94
-$0.95
-$0.82
-$0.88
Recent news
Company coverage with links to the original publishers.
Kymera Therapeutics reported Q3 2026 financial results with positive Phase 1 data for KT-579 (IRF5 degrader) showing deep, sustained target degradation and favorable safety profile. The company is advancing KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, with AD topline data expected by year-end 2026. Kymera maintains strong financial position with $1.6 billion in cash providing runway into 2029.
Axsome Therapeutics is expected to report a quarterly loss of $0.65 per share with revenues of $249.32 million when it releases Q3 2026 earnings on November 2. However, analyst estimates have been revised 70.27% lower over the last 30 days, and the company's Earnings ESP of -11.79% combined with a Zacks Rank #3 makes it difficult to predict an earnings beat. The company has failed to beat consensus EPS estimates in the last four quarters.
Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.
Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6 million on July 7, 2026, following a 170% stock surge over 12 months. The sale involved exercising options at $2.08 and selling at $119 per share under a pre-scheduled Rule 10b5-1 trading plan. Despite the sale, Mainolfi retains 666,568 shares worth $79.5 million and 90,000 options, indicating continued confidence in the company's pipeline, particularly KT-621 in Phase 2b trials with FDA Fast Track status.
Kymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at Day 7). The company has parallel Phase 2b trials ongoing in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late 2027, respectively.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.